Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2021 May 12;22(10):5097.
doi: 10.3390/ijms22105097.

Antimicrobial Activities of LL-37 Fragment Mutant-Poly (Lactic-Co-Glycolic) Acid Conjugate against Staphylococcus aureus, Escherichia coli, and Candida albicans

Affiliations
Comparative Study

Antimicrobial Activities of LL-37 Fragment Mutant-Poly (Lactic-Co-Glycolic) Acid Conjugate against Staphylococcus aureus, Escherichia coli, and Candida albicans

Takeshi Mori et al. Int J Mol Sci. .

Abstract

Various peptides and their derivatives have been reported to exhibit antimicrobial activities. Although these activities have been examined against microorganisms, novel methods have recently emerged for conjugation of the biomaterials to improve their activities. Here, we prepared CKR12-PLGA, in which CKR12 (a mutated fragment of human cathelicidin peptide, LL-37) was conjugated with poly (lactic-co-glycolic) acid (PLGA), and compared the antimicrobial and antifungal activities of the conjugated peptide with those of FK13 (a small fragment of LL-37) and CKR12 alone. The prepared CKR12-PLGA was characterized by dynamic light scattering and measurement of the zeta potential, critical micellar concentration, and antimicrobial activities of the fragments and conjugate. Although CKR12 showed higher antibacterial activities than FK13 against Staphylococcus aureus and Escherichia coli, the antifungal activity of CKR12 was lower than that of FK13. CKR12-PLGA showed higher antibacterial activities against S. aureus and E. coli and higher antifungal activity against Candida albicans compared to those of FK13. Additionally, CKR12-PLGA showed no hemolytic activity in erythrocytes, and scanning and transmission electron microscopy suggested that CKR12-PLGA killed and disrupted the surface structure of microbial cells. Conjugation of antimicrobial peptide fragment analogues was a successful approach for obtaining increased microbial activity with minimized cytotoxicity.

Keywords: antimicrobial peptide; conjugation with poly (lactic-co-glycolic) acid; mutant peptide; scanning electron microscopy; transmission electron microscopy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest to disclose.

Figures

Figure 1
Figure 1
Predicted structures of LL-37, FK13, and CKR12. Fragmented sequence in LL-37 is underlined, and mutated residues in CKR12 are enclosed in the sequence of FK13. The predicted secondary structures are represented underneath the sequences as “H” for helical and “-” for random coiled structures.
Figure 2
Figure 2
Summary of synthesis of CKR12-PLGA conjugate via a cleavable disulfide linkage. CKR12 is shown as a cylinder.
Figure 3
Figure 3
Particle size (A) and zeta potential values (B) of CKR12-PLGA conjugate micelle.
Figure 4
Figure 4
Scanning electron microscopic images of S. aureus (A), E. coli (B), and C. albicans (C) cells in the absence (left panel) and presence (right panel) of 110 µM CKR12-PLGA.
Figure 5
Figure 5
Transmission electron microscope images of S. aureus (A), E. coli (B), and C. albicans (C) cells. The microorganisms are shown in the absence (left panel) and presence (right panel) of 61.3 µM CKR12-PLGA.
Figure 6
Figure 6
Schematic mechanisms of individual and self-assembled micelles of CKR12-PLGA against S. aureus, E. coli, and C. albicans.

Similar articles

Cited by

References

    1. Mercer D.K., Torres M.D.T., Duay S.S., Lovie E., Simpson L., von Kockritz-Blickwede M., de la Fuente-Nunez C., O’Neil D.A., Angeles-Boza A.M. Antimicrobial Susceptibility Testing of Antimicrobial Peptides to Better Predict Efficacy. Front. Cell Infect. Microbiol. 2020;10:326. doi: 10.3389/fcimb.2020.00326. - DOI - PMC - PubMed
    1. Guterstam P., Madani F., Hirose H., Takeuchi T., Futaki S., El Andaloussi S., Graslund A., Langel U. Elucidating cell-penetrating peptide mechanisms of action for membrane interaction, cellular uptake, and translocation utilizing the hydrophobic counter-anion pyrenebutyrate. Biochim. Biophys. Acta. 2009;1788:2509–2517. doi: 10.1016/j.bbamem.2009.09.014. - DOI - PubMed
    1. De la Fuente-Nunez C., Silva O.N., Lu T.K., Franco O.L. Antimicrobial peptides: Role in human disease and potential as immunotherapies. Pharmacol. Ther. 2017;178:132–140. doi: 10.1016/j.pharmthera.2017.04.002. - DOI - PubMed
    1. Felicio M.R., Silva O.N., Goncalves S., Santos N.C., Franco O.L. Peptides with Dual Antimicrobial and Anticancer Activities. Front. Chem. 2017;5:5. doi: 10.3389/fchem.2017.00005. - DOI - PMC - PubMed
    1. Silva O.N., Mulder K.C., Barbosa A.E., Otero-Gonzalez A.J., Lopez-Abarrategui C., Rezende T.M., Dias S.C., Franco O.L. Exploring the pharmacological potential of promiscuous host-defense peptides: From natural screenings to biotechnological applications. Front. Microbiol. 2011;2:232. doi: 10.3389/fmicb.2011.00232. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources